Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chanah Gallagher"'
Publikováno v:
Open Forum Infectious Diseases. 9
Background The Oral versus Intravenous Antibiotics for Bone and Joint Infection Trial concluded that oral antibiotics administered during the first six weeks of therapy for orthopedic infections were non-inferior to parenteral antibiotics. Previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c95fe8b424e806658b8a7736eb60897
https://doi.org/10.1093/ofid/ofac492.754
https://doi.org/10.1093/ofid/ofac492.754
Publikováno v:
Open Forum Infectious Diseases
Background The Oral versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial determined oral antibiotics administered during the first six weeks of therapy were non-inferior to parenteral antibiotics. There was no difference in the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59594fe95465dcc6d90958e41212b6e7
http://europepmc.org/articles/PMC8644536
http://europepmc.org/articles/PMC8644536
Publikováno v:
Open Forum Infectious Diseases
Background CRE are a world-wide public health challenge with extremely limited treatment options. Aminoglycosides have variable susceptibility against these organisms. At our institution, amikacin has been active against these isolates and useful as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::744f1800ec079d82123a2ee19b4ff4c6
https://doi.org/10.1093/ofid/ofx163.1554
https://doi.org/10.1093/ofid/ofx163.1554
Autor:
David S. Burgess, Julie A. Ribes, Brandon Kulengowski, Chanah Gallagher, Matthew Brignola, W. Cliff Rutter
Publikováno v:
Open Forum Infectious Diseases
Background Polymyxins are being revitalized to combat carbapenem-resistant Enterobacteriaceae (CRE). However, evaluating the activity of these agents by traditional broth dilution methods is not practical for busy clinical laboratories. We compared p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c802bf28ada704a5b4f52a9ff2fe52b
http://europepmc.org/articles/PMC5631111
http://europepmc.org/articles/PMC5631111
Publikováno v:
Open Forum Infectious Diseases. 2023 Supplement, Vol. 10, pS1-S1274. 3913p.
Publikováno v:
Pharmacotherapy; Dec2023, Vol. 43 Issue 12, p1277-1285, 9p
Autor:
Gallagher, Chanah
Pseudomonas aeruginosa causes severe healthcare-associated infections. Forty-eight extensively drug-resistant (XDR)-P. aeruginosa isolates were selected from 287 isolates collected for evaluation based on clinical susceptibility data. In vitro activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f92069d01d605aca2335eea8f613a17
